SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (1534)7/15/1998 6:46:00 PM
From: Y2k_fan  Respond to of 4634
 
I also remember that you said that you were 100% certain AVNT's Aquarius will be immediately enjoined. (Which I agree, but not as immediately.)

Next time, I will just deduct 20% from your 100%.



To: Bill Wexler who wrote (1534)7/15/1998 8:38:00 PM
From: Dante Sinferno  Respond to of 4634
 
<< I am 100% certain that Vasomax will be rejected.>>

For those playing at home , how long is the process
from this point ?

Rob



To: Bill Wexler who wrote (1534)7/16/1998 6:02:00 AM
From: Graeme Smith  Read Replies (1) | Respond to of 4634
 
Why do you believe that Vasomax will be rejected. I don't follow Biotechs too much, but if Vasomax has few side effects, and is beneficial for some people, why would it be rejected. Once in the market place it would fail because there are better alternatives. Will FDA reject a drug just because it is less effective than its competitors?

Thanks,

Graeme


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News